(Reuters) -Metsera said on Monday that its experimental obesity drug showed significant weight loss and favorable tolerability in mid-stage studies.
The drug, MET-097i, led to a placebo-adjusted weight loss of up to 14.1% after 28 weekly doses in a mid-stage study, the company said.
MET-097i also showed tolerability in patients without type 2 diabetes who are overweight or have obesity.
Pfizer said last week that it would buy Metsera in a deal valued at up to $7.3 billion, including future payments, as it seeks a foothold in the fast-growing obesity treatment market.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Sahal Muhammed)
Brought to you by www.srnnews.com
